ATNM (Actinium Pharmaceuticals) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATNM Actinium Pharmaceuticals Inc ATNM
17 GF Score
Price $1.22
! 5 Warning Signs
View Full Analysis

What is Actinium Pharmaceuticals Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

ATNM
17GF Score
Actinium Pharmaceuticals Inc ATNM
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actinium Pharmaceuticals Business Description

Other Exchanges 7AY1:Germany
Address 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in the United States that develops targeted radiotherapies for cancer and other serious diseases. Its core technology is the Antibody Radiation Conjugate (ARC) platform, which links monoclonal antibodies to radioisotopes so that radiation is delivered selectively to target cells. The company's lead candidates include Iomab-B, an iodine-131 based therapy studied as conditioning before hematopoietic stem cell transplant in older patients with acute myeloid leukemia, and Actimab-A, an actinium-225 based therapy developed for acute myeloid leukemia. Actinium is also advancing Iomab-ACT for conditioning in cell and gene therapy, along with earlier-stage and preclinical programs, including solid tumor applications. As a clinical-stage company, it has no approved products and generates no meaningful product revenue, funding operations primarily through equity financings, partnerships, and research collaborations with academic and industry partners.
17GF Score

Get the complete analysis for ATNM

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.22
Price